0 followers
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor ty... Read more
Matt Outten
Elemental Enzymes
1 follower
Thermo Fisher Scientific
174 followers
Gilead Sciences
133 followers
Regeneron
101 followers
BioMarin Pharmaceutical
36 followers
10X Genomics
13 followers
VaxCare
1 follower
Spectrix Analytical Services
1 follower
Sage Therapeutics
5 followers
Foundation Medicine
5 followers
AbbVie
191 followers
Explore companies